Report error Found 771 Enz. Inhib. hit(s) with Target = 'Isoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)'
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.0250nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.0320nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.0400nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.0400nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.0400nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.0500nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.0540nMpH: 7.5 T: 2°CAssay Description:A human acute lymphoblastic lymphoma T cell line MOLT-4 (which can be purchased under ATCC No. CRL-1582 from ATCC) was cultured in an RPMI1640 medium...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.0790nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.0790nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.0790nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.0790nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.0790nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.0850nMpH: 7.5 T: 2°CAssay Description:A human acute lymphoblastic lymphoma T cell line MOLT-4 (which can be purchased under ATCC No. CRL-1582 from ATCC) was cultured in an RPMI1640 medium...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.100nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.102nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.102nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.102nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.110nMpH: 7.5 T: 2°CAssay Description:A human acute lymphoblastic lymphoma T cell line MOLT-4 (which can be purchased under ATCC No. CRL-1582 from ATCC) was cultured in an RPMI1640 medium...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.110nMpH: 7.5 T: 2°CAssay Description:A human acute lymphoblastic lymphoma T cell line MOLT-4 (which can be purchased under ATCC No. CRL-1582 from ATCC) was cultured in an RPMI1640 medium...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.110nMpH: 7.5 T: 2°CAssay Description:A human acute lymphoblastic lymphoma T cell line MOLT-4 (which can be purchased under ATCC No. CRL-1582 from ATCC) was cultured in an RPMI1640 medium...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.112nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.120nMpH: 7.5 T: 2°CAssay Description:A human acute lymphoblastic lymphoma T cell line MOLT-4 (which can be purchased under ATCC No. CRL-1582 from ATCC) was cultured in an RPMI1640 medium...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.120nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.120nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.126nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.150nMpH: 7.5 T: 2°CAssay Description:A human acute lymphoblastic lymphoma T cell line MOLT-4 (which can be purchased under ATCC No. CRL-1582 from ATCC) was cultured in an RPMI1640 medium...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.158nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.174nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.210nMpH: 7.5 T: 2°CAssay Description:A human acute lymphoblastic lymphoma T cell line MOLT-4 (which can be purchased under ATCC No. CRL-1582 from ATCC) was cultured in an RPMI1640 medium...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.220nMpH: 7.5 T: 2°CAssay Description:A human acute lymphoblastic lymphoma T cell line MOLT-4 (which can be purchased under ATCC No. CRL-1582 from ATCC) was cultured in an RPMI1640 medium...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.230nMpH: 7.5 T: 2°CAssay Description:A human acute lymphoblastic lymphoma T cell line MOLT-4 (which can be purchased under ATCC No. CRL-1582 from ATCC) was cultured in an RPMI1640 medium...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.230nMpH: 7.5 T: 2°CAssay Description:A human acute lymphoblastic lymphoma T cell line MOLT-4 (which can be purchased under ATCC No. CRL-1582 from ATCC) was cultured in an RPMI1640 medium...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.260nMpH: 7.5 T: 2°CAssay Description:A human acute lymphoblastic lymphoma T cell line MOLT-4 (which can be purchased under ATCC No. CRL-1582 from ATCC) was cultured in an RPMI1640 medium...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.290nMpH: 7.5 T: 2°CAssay Description:A human acute lymphoblastic lymphoma T cell line MOLT-4 (which can be purchased under ATCC No. CRL-1582 from ATCC) was cultured in an RPMI1640 medium...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.290nMpH: 7.5 T: 2°CAssay Description:A human acute lymphoblastic lymphoma T cell line MOLT-4 (which can be purchased under ATCC No. CRL-1582 from ATCC) was cultured in an RPMI1640 medium...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.295nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.300nMpH: 7.5 T: 2°CAssay Description:A human acute lymphoblastic lymphoma T cell line MOLT-4 (which can be purchased under ATCC No. CRL-1582 from ATCC) was cultured in an RPMI1640 medium...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.310nMpH: 7.5Assay Description:Inhibitory activity-1 assay: To a solution containing 20 mM Tris-HCl (pH 7.5), 1 mM MgCl2, 100 μM EDTA, 330 μg/ml bovine serum albumin, 50 ...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.310nMpH: 7.5 T: 2°CAssay Description:A human acute lymphoblastic lymphoma T cell line MOLT-4 (which can be purchased under ATCC No. CRL-1582 from ATCC) was cultured in an RPMI1640 medium...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.310nMpH: 7.5 T: 2°CAssay Description:A human acute lymphoblastic lymphoma T cell line MOLT-4 (which can be purchased under ATCC No. CRL-1582 from ATCC) was cultured in an RPMI1640 medium...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.324nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.340nMpH: 7.5 T: 2°CAssay Description:A human acute lymphoblastic lymphoma T cell line MOLT-4 (which can be purchased under ATCC No. CRL-1582 from ATCC) was cultured in an RPMI1640 medium...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.350nMpH: 7.5 T: 2°CAssay Description:A human acute lymphoblastic lymphoma T cell line MOLT-4 (which can be purchased under ATCC No. CRL-1582 from ATCC) was cultured in an RPMI1640 medium...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.350nMpH: 7.5 T: 2°CAssay Description:A human acute lymphoblastic lymphoma T cell line MOLT-4 (which can be purchased under ATCC No. CRL-1582 from ATCC) was cultured in an RPMI1640 medium...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.370nMpH: 7.5 T: 2°CAssay Description:A human acute lymphoblastic lymphoma T cell line MOLT-4 (which can be purchased under ATCC No. CRL-1582 from ATCC) was cultured in an RPMI1640 medium...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.372nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.380nMpH: 7.5 T: 2°CAssay Description:A human acute lymphoblastic lymphoma T cell line MOLT-4 (which can be purchased under ATCC No. CRL-1582 from ATCC) was cultured in an RPMI1640 medium...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.389nMAssay Description:Semi Log compound dilutions starting at a final concentration of 50 μM were dispensed into a black 384 well plate alongside, DMSO and an Inhibit...More data for this Ligand-Target Pair
Ligand InfoSimilars
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.390nMpH: 7.5 T: 2°CAssay Description:A human acute lymphoblastic lymphoma T cell line MOLT-4 (which can be purchased under ATCC No. CRL-1582 from ATCC) was cultured in an RPMI1640 medium...More data for this Ligand-Target Pair
TargetIsoform PDE10A2 of cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A2)(Human)
Benevolentai Cambridge
US Patent
Benevolentai Cambridge
US Patent
Affinity DataIC50: 0.410nMpH: 7.5Assay Description:Inhibitory activity-1 assay: To a solution containing 20 mM Tris-HCl (pH 7.5), 1 mM MgCl2, 100 μM EDTA, 330 μg/ml bovine serum albumin, 50 ...More data for this Ligand-Target Pair












































